The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both ...
Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...
Veracyte (VCYT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda ...
As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...
The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...
A doctor at the centre of a review of the treatment of more than 200 patients with lung disease is being investigated by the ...
The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback